Back to feed

NCT06840821

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

A Phase I/II, Multicenter, Open-label, Single-arm, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 Sequential Therapy in Adult Subjects With Advanced Solid Tumors (Including Gastroenteropancreatic Neuroendocrine Neoplasms, Small Cell Lung Cancer or Triple Negative Breast Cancer)

ClinicalTrials.gov
Sponsor
Mainline Biosciences (Shanghai) Co., Ltd
Status
Recruiting
Versions
4
Adjacent patches
3
Severity is deterministic, reproducible, uncalibrated triage metadata, not validated review priority or proven wrongdoing. New Evidence Record packages are generated for deterministic event-class membership, not by triage rank alone.

Material event timeline

3 shown
Triage: High
2025-05-19
Eligibility Change
v0 to v1 Pre Recruitment Inspect patch
/protocolSection/contactsLocationsModule/locations
/protocolSection/descriptionModule/briefSummary
/protocolSection/eligibilityModule/eligibilityCriteria
Triage: High
2025-05-21
Eligibility Change
v1 to v2 Early Recruitment Inspect patch
/protocolSection/eligibilityModule/eligibilityCriteria
/protocolSection/statusModule/lastUpdatePostDateStruct/date
/protocolSection/statusModule/lastUpdateSubmitDate
Triage: High
2025-11-30
Eligibility Change
v2 to v3 Early Recruitment Inspect patch
/protocolSection/eligibilityModule/eligibilityCriteria
/protocolSection/oversightModule/isUsExport
/protocolSection/statusModule/lastUpdatePostDateStruct/date